Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dabrafenib and trametinib in BRAFV600E mutated glioma.

CNS oncology - 1 Oct 2017

Brown Nicholas F, Carter Thomas, Kitchen Neil, Mulholland Paul

Abstract excerpt

BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with BRAFV600E mutant tumors, resistance develops in a majority of patients due to reactivation of the MAPK pathway....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 28984141
DOI: 10.2217/cns-2017-0006
PMCID: PMC6004887

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dabrafenib and trametinib in BRAFV600E mutated glioma.PMID 28984141Read ↗

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.Semantic proximity Read ↗

Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases.Semantic proximity Read ↗

Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation.Semantic proximity Read ↗

Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.Semantic proximity Read ↗

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.Semantic proximity Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.Semantic proximity Read ↗

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.Semantic proximity Read ↗

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma.Semantic proximity Read ↗

Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.Semantic proximity Read ↗

A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.